Article Text

Original article
Eosinophil-mediated signalling attenuates inflammatory responses in experimental colitis
  1. Joanne C Masterson1,2,3,
  2. Eóin N McNamee2,3,4,
  3. Sophie A Fillon1,2,3,
  4. Lindsay Hosford1,2,3,
  5. Rachel Harris1,2,3,
  6. Shahan D Fernando1,2,3,
  7. Paul Jedlicka3,5,
  8. Ryo Iwamoto6,
  9. Elizabeth Jacobsen7,8,
  10. Cheryl Protheroe7,8,
  11. Holger K Eltzschig2,3,4,
  12. Sean P Colgan2,3,9,
  13. Makoto Arita6,7,
  14. James J Lee8,
  15. Glenn T Furuta1,2,3
  1. 1Section of Pediatric Gastroenterology, Hepatology and Nutrition, Gastrointestinal Eosinophilic Diseases Program, Department of Pediatrics; Digestive Health Institute, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA
  2. 2Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colorado, USA
  3. 3University of Colorado School of Medicine, Aurora, Colorado, USA
  4. 4Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado, USA
  5. 5Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado, USA
  6. 6Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan
  7. 7Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Japan
  8. 8Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
  9. 9Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
  1. Correspondence to Dr Glenn T Furuta, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Colorado School of Medicine, 13123 East 16th Ave, B290, Aurora, CO 80045, USA; glenn.furuta{at}childrenscolorado.org

Abstract

Objective Eosinophils reside in the colonic mucosa and increase significantly during disease. Although a number of studies have suggested that eosinophils contribute to the pathogenesis of GI inflammation, the expanding scope of eosinophil-mediated activities indicate that they also regulate local immune responses and modulate tissue inflammation. We sought to define the impact of eosinophils that respond to acute phases of colitis in mice.

Design Acute colitis was induced in mice by administration of dextran sulfate sodium, 2,4,6-trinitrobenzenesulfonic acid or oxazolone to C57BL/6J (control) or eosinophil deficient (PHIL) mice. Eosinophils were also depleted from mice using antibodies against interleukin (IL)-5 or by grafting bone marrow from PHIL mice into control mice. Colon tissues were collected and analysed by immunohistochemistry, flow cytometry and reverse transcription PCR; lipids were analysed by mass spectroscopy.

Results Eosinophil-deficient mice developed significantly more severe colitis, and their colon tissues contained a greater number of neutrophils, than controls. This compensatory increase in neutrophils was accompanied by increased levels of the chemokines CXCL1 and CXCL2, which attract neutrophils. Lipidomic analyses of colonic tissue from eosinophil-deficient mice identified a deficiency in the docosahexaenoic acid-derived anti-inflammatory mediator 10, 17- dihydroxydocosahexaenoic acid (diHDoHE), namely protectin D1 (PD1). Administration of an exogenous PD1-isomer (10S, 17S-DiHDoHE) reduced the severity of colitis in eosinophil-deficient mice. The PD1-isomer also attenuated neutrophil infiltration and reduced levels of tumour necrosis factor-α, IL-1β, IL-6 and inducible NO-synthase in colons of mice. Finally, in vitro assays identified a direct inhibitory effect of PD1-isomer on neutrophil transepithelial migration.

Conclusions Eosinophils exert a protective effect in acute mouse colitis, via production of anti-inflammatory lipid mediators.

  • MUCOSAL IMMUNOLOGY
  • IBD BASIC RESEARCH
  • IMMUNOREGULATION
  • INFLAMMATION
  • LIPID MEDIATORS

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement: